Theriva Biologics (TOVX) Current Assets (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Current Assets of $16.8 million for Q1 2026, up 34.31% year-over-year from $12.5 million in Q1 2025, and down 4.06% quarter-over-quarter from $17.5 million in Q4 2025.
Theriva Biologics (TOVX) Current Assets (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Current Assets for 17 consecutive years, with $16.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 34.31% year-over-year to $16.8 million; the TTM figure through Mar 2026 stood at $16.8 million (up 34.31% YoY), while the FY2025 annual figure was $17.5 million, up 7.28% from the prior year.
- Current Assets retreated to $16.8 million in Q1 2026 per TOVX's latest filing, from $17.5 million in the prior quarter.
- Across five years, Current Assets topped out at $59.6 million in Q1 2022 and bottomed at $9.9 million in Q3 2025.
- Historically, Current Assets has averaged $29.5 million across 5 years, with a median of $21.7 million in 2024.
- Annual changes were most pronounced in 2025 — Current Assets slumped 49.3% — and 2026, when it jumped 34.31%.
- Theriva Biologics' Current Assets stood at $45.5 million in 2022, then tumbled by 39.8% to $27.4 million in 2023, then tumbled by 40.59% to $16.3 million in 2024, then increased by 7.28% to $17.5 million in 2025, then declined by 4.06% to $16.8 million in 2026.
- Business Quant data shows TOVX's Current Assets at $16.8 million in Q1 2026, $17.5 million in Q4 2025, and $9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 1.76 Bn |
| 10 | Theriva Biologics | 10.95 Mn | 10.95 Mn | - | 13.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.67 Mn |
| Mar 31, 2026 | 16.76 Mn |
| Dec 31, 2025 | 17.47 Mn |
| Sep 30, 2025 | 9.90 Mn |
| Jun 30, 2025 | 14.74 Mn |
| Mar 31, 2025 | 12.48 Mn |
| Dec 31, 2024 | 16.28 Mn |
| Sep 30, 2024 | 19.53 Mn |
| Jun 30, 2024 | 19.72 Mn |
| Mar 31, 2024 | 21.66 Mn |
| Dec 31, 2023 | 27.40 Mn |
| Sep 30, 2023 | 34.77 Mn |
| Jun 30, 2023 | 37.97 Mn |
| Mar 31, 2023 | 40.30 Mn |
| Dec 31, 2022 | 45.52 Mn |
| Sep 30, 2022 | 52.73 Mn |
| Jun 30, 2022 | 54.89 Mn |
| Mar 31, 2022 | 59.56 Mn |
| Dec 31, 2021 | 68.86 Mn |
| Sep 30, 2021 | 73.56 Mn |